Close

We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to www.arthritisresearchuk.org

Our experimental treatment centres

Arthritis Research UK has established a network of experimental arthritis and osteoarthritis treatment centres to facilitate and support the testing and early development of novel interventions in the treatment of arthritis and related conditions:

Experimental arthritis treatment centres

Each EATC receives up to a maximum of £75,000 per annum for five years. Support is for three years, renewable for a further two based on activity after which time the scheme will be reviewed.

Eight experimental arthritis treatment centres (EATCs) have been awarded, based on competitive application and external review. Each award provides additional support to an existing experimental treatment resource to yield an enhanced platform for the delivery of ‘first in man’ / ‘first in disease’ studies of novel arthritis therapies.

EATC location

Grant holder

Birmingham

Christopher Buckley

Cardiff

Ernest Choy

Glasgow

Iain McInnes

King's College London

Andrew Cope

Newcastle

John Isaacs

Oxford

Peter Taylor

Queen Mary University of London

Costantino Pitzalis

Liverpool

Michael Beresford 

Experimental osteoarthritis treatment centres

We have also established two experimental osteoarthritis treatment centres (EOTCs) with the remit to test the role of novel biomechanical interventions for the primary and secondary prevention of osteoarthritis, particularly of the knee.

The EOTCs are based in institutions with expertise in clinical studies of osteoarthritis interventions and in undertaking the necessary detailed patient characterisation (imaging, gait analysis and other relevant investigations) to assess mechanisms of action and appropriate phenotypes for intervention.

Funding provides support for infrastructure, grant holders are be expected to build on this to deliver a platform of studies testing novel biomechanical interventions working where appropriate with suitable industry partners. The EOTCs receive up to a maximum of £50,000 per annum for five years. Support will be for three years, renewable for a further two based on activity after which time the scheme will be reviewed.

EOTC location

Grant holder

Leeds

Philip Conaghan

Oxford

Andrew Price

For more information, go to www.arthritisresearchuk.org.
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.